Although acetaminophen is the most common drug for treating pain and fever, and also the most common cause of life threatening drug-induced liver damage, there are no tests that specifically diagnose a liver-injury from an overdose. The object of this grant is to complete the development of AcetaSTAT(r), an innovative new method to diagnose an acetaminophen overdose. The new test was developed by Acetaminophen Toxicity Diagnostics LLC (ATD) in conjunction with the University of Arkansas for Medical Sciences (UAMS) and the Arkansas Children's Hospital Research Institute (ACHRI). The advantage of AcetaSTAT(r) is that, unlike existing tests, it is fast, easy and specific to acetaminophen toxicity. This will allow clinicians to quickly and accurately prescribe the correct treatment that will help patients and reduce costs. The proposed work will result in ATD, a privately held company, obtaining FDA clearance of AcetaSTAT(r) so that it can be made available to practicing physicians. The proposed work will: 1) develop the final version of AcetaSTAT(r) using a monoclonal antibody, 2) produce AcetaSTAT(r) in a good manufacturing practices (GMP) laboratory, and 3) test the clinical performance of AcetaSTAT(r) in a wide range of patient exposures to acetaminophen. ATD will continue to work closely with the FDA to ensure that product development and clinical trials are compliant with FDA requirements for AcetaSTAT(r) to be cleared for commercial sales in the US.
Acetaminophen Toxicity Diagnostics, LLC (ATD) has developed a rapid, point-of-care blood test (AcetaSTAT) that will help the diagnoses and treatment of patients that are at risk of dying from liver failure because they have taken too much acetaminophen. This research will fund the final development of AcetaSTAT so that it meets all the criteria to be marketed in the United States. This rapid, point-of-care test is important because acetaminophen is the most commonly used drug for pain and the most common cause of drug-induced liver damage. There are currently no FDA approved tests for the diagnosis of liver toxicity from acetaminophen overdose. The test will significantly improve the standard of care given to patients by providing information to doctors about the cause of liver injury, which will guide treatment decisions.
|Roberts, Dean W; Lee, William M; Hinson, Jack A et al. (2017) An Immunoassay to Rapidly Measure Acetaminophen Protein Adducts Accurately Identifies Patients With Acute Liver Injury or Failure. Clin Gastroenterol Hepatol 15:555-562.e3|
|Dobson, Nicole R; Liu, Xiaoxi; Rhein, Lawrence M et al. (2016) Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy. Br J Clin Pharmacol 82:754-61|
|James, Laura; Yan, Ke; Pence, Lisa et al. (2015) Comparison of Bile Acids and Acetaminophen Protein Adducts in Children and Adolescents with Acetaminophen Toxicity. PLoS One 10:e0131010|
|James, Laura; Roberts, Dean (2014) Isoniazid hepatotoxicity: progress in understanding the immunologic component. Hepatology 59:746-8|
|James, Laura P; Gill, Prit; Simpson, Pippa (2013) Predicting risk in patients with acetaminophen overdose. Expert Rev Gastroenterol Hepatol 7:509-12|
|James, Laura P; Chiew, Angela; Abdel-Rahman, Susan M et al. (2013) Acetaminophen protein adduct formation following low-dose acetaminophen exposure: comparison of immediate-release vs extended-release formulations. Eur J Clin Pharmacol 69:851-7|
|James, L; Ito, S (2009) Neonatal pharmacology: rational therapeutics for the most vulnerable. Clin Pharmacol Ther 86:573-7|